Evotec
Hirokazu Fukui has a strong career history in the field of scientific research. Hirokazu started their professional journey at Stanford University as a Postdoctoral Fellow from June 2008 to June 2009. Hirokazu then joined the Center for Regenerative Therapies Dresden as a Postdoctoral Fellow from July 2009 to September 2011. In 2011, Hirokazu joined Evotec, where they have held various roles. Hirokazu began as a Research Associate from October 2011 to March 2013 and then progressed to become a Research Scientist from April 2013 to November 2022. From April 2018, they took on the position of Senior Research Scientist at Evotec. Their most recent role is Principal Scientist, which they started in November 2022 and is currently ongoing.
Hirokazu Fukui holds a Ph.D. in Neuroscience from the University of Miami, where they studied from 2003 to 2008. Prior to that, they completed their M.S. in Biological Sciences at Georgia College & State University from 2001 to 2003. Their undergraduate education was at Kobe Pharmaceutical University, where they obtained a B.S. in Pharmacy/Pharmaceutical Sciences from 1997 to 2001. In addition, they have certifications such as the EF SET English Certificate 76/100 (C2 Proficient) obtained in 2019 and the Pharmacist certification in Japan obtained in 2001.
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.